MEDCAST
Monoclonal Antibodies: a Stanford Story
of Academia-Industry Collaboration
|
|
|
 Duration: 51 min |
|
|
|
Since the 1970s, Ron Levy, MD, professor of medicine, has been exploring ways to harness the body's immune system to fight cancer. In 1976, he found that it was possible to make monoclonal antibodies that could specifically recognize cancer cells inside the body and tag them for destruction. This work led to the development of Rituxan, the first FDA-approved monoclonal antibody for cancer treatment. Today Rituxan is used to treat more than 500,000 people each year. Levy recounts his experiences moving his discovery from the lab to the clinical setting and discusses the future of this cancer treatment. Wendy Harpham, a participant in the early clinical trials of Rituxan, provides a patient’s perspective. Related News: |
|
|
|
|
|
|
|
About this podcastPosted: 09/05/07
